What is myPath® Melanoma?

myPath Melanoma provides confidence to personalize patient treatment recommendations.

The analysis of biopsied tissue using a microscope (histopathology) has long been the standard of care for melanoma diagnosis. While it is adequate for diagnosis in most cases, evidence suggests that approximately 10-15% of biopsied melanocytic lesions may be histopathologically ambiguous.2-5 In these situations, microscopic examination may reveal a few features that are characteristic of melanoma but others that are more typical of a benign nevus (‘mole’). As a result, even experienced dermatopathologists occasionally disagree as to whether a given melanocytic lesion is benign or malignant.

Myriad Genetic Laboratories

Myriad Genetic Laboratories has developed myPath® Melanoma, a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone.

The test measures the expression of 23 genes by qRT-PCR methodology and distinguishes melanoma from nevi with a sensitivity of 90-94% and a specificity of 91-96%. 7,29,30

90% - 94%


91% - 96%


How the myPath Melanoma test works

The myPath Melanoma test measures 23 genes for which expression patterns differ between malignant melanoma and benign nevi. These genes are involved in cell differentiation, cell signaling, and immune response signaling.

The genes include:

  • PRAME a single gene involved in cell differentiation
  • S100A7, S100A8, S100A9, S100A12 and PI3, a group of genes involved in multiple cell signaling pathways
  • CCL5, CD38, CXCL10, CXCL9, IRF1, LCP2, PTPRC and SELL involved in tumor immune response signaling
  • Nine reference genes that are measured to normalize RNA expression for analysis

Gene Components

Reference genes included: CLTC, MRFAPI, PPP2CA, PSMA1, RPL13A, RPL8, RPS29, SLC25A3, and TXNLI

The result is a single numerical score

An algorithm is applied that combines the measurements of gene expression, assigns a weight to each gene component, and establishes a threshold value.

The result is a single numerical score that classifies a melanocytic lesion as ‘likely benign’, ‘likely malignant’, or ‘indeterminate’.

myPath Melanoma has been clinically validated utilizing rigorous laboratory processes to produce a precise and reproducible result.

myPath Melanoma is currently available throughout the country.

Myriad Corporate Headquarters

(800) 231-4442

320 Wakara Way

Salt Lake City, UT 84108


References     Contact     Notice of Privacy Practices     Terms of Use    Privacy Policy

Copyright © 2019 Myriad myPath Melanoma. All rights reserved.